Fig. 2From: An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 studyKaplan–Meier plot of survival proportion with 95% confidence interval according to time from baseline. Dashed line, 95% confidence interval; solid line, Kaplan–Meier survival curveBack to article page